1	Phenome-wide Mendelian randomization study of plasma triglycerides and 2,600 disease traits
2	
3	Short Title: Phenome-wide Mendelian randomization study of plasma triglycerides
4	
5	Joshua K. Park <sup>1,2,3*</sup> , Shantanu Bafna <sup>1,2,*</sup> , Iain S. Forrest <sup>1,2,3</sup> , Áine Duffy <sup>1,2</sup> , Carla Marquez-
6	Luna <sup>1,2</sup> , Ben O. Petrazzini <sup>1,2</sup> , Ha My Vy <sup>1,2</sup> , Daniel M. Jordan <sup>1,2</sup> , Marie Verbanck <sup>4</sup> , Jagat
7	Narula <sup>5,6</sup> , Robert S. Rosenson <sup>5,7</sup> , Ghislain Rocheleau <sup>1,2</sup> , Ron Do <sup>1,2,†</sup>
8	
9	<sup>1</sup> Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount
10	Sinai, New York, NY, USA
11	<sup>2</sup> Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New
12	York, NY, USA
13	<sup>3</sup> Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, NY,
14	USA
15	<sup>4</sup> Université Paris Cité, UR 7537 BioSTM, Paris, France
16	<sup>5</sup> Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
17	<sup>6</sup> Cardiovascular Imaging Program, Zena and Michael A. Wiener Cardiovascular Institute, Mount
18	Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY
19	<sup>7</sup> Metabolism and Lipids Unit, Zena and Michael A. Wiener Cardiovascular Institute, Mount
20	Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY
21	*These authors contributed equally to this work.
22	<sup>†</sup> Corresponding author
23	E-mail: <u>ron.do@mssm.edu</u> (RD)

24	Abbreviations: ALD, alcoholic liver disease; ANGPTL3, angiopoietin-like 3; ANGPTL4,
25	angiopoietin-like 4; ApoB, apolipoprotein B; APOC3, apolipoprotein C-III; ASCVD,
26	atherosclerotic cardiovascular disease; CAD, coronary artery disease; GLGC, Global Lipids
27	Genetics Consortium; HDL-C, high-density lipoprotein cholesterol; IHD, ischemic heart disease;
28	IV, instrumental variable; LDL-C, low-density lipoprotein cholesterol; MR-PRESSO, Mendelian
29	randomization pleiotropy residual sum and outlier; MVMR, Multivariable Mendelian
30	randomization; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; REDUCE-IT,
31	Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial; STRENGTH,
32	STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With
33	Hypertriglyceridemia; TG, triglyceride
34	
35	Keywords: Cardiovascular disease; Coronary artery disease; Dyslipidemia; FinnGen;
36	Hypertriglyceridemia; Lipids; Mendelian randomization; Phenome-wide MR; Triglyceride-rich

37 lipoprotein; Triglycerides; UK Biobank

## 39 Abstract

Background: Causality between plasma triglyceride (TG) levels and atherosclerotic
cardiovascular disease (ASCVD) risk remains controversial despite more than four decades of
study and two recent landmark trials, STRENGTH and REDUCE-IT. Further unclear is the
association between TG levels and non-atherosclerotic diseases across organ systems.

44

45 **Methods:** Here, we conducted a phenome-wide, two-sample Mendelian randomization (MR) 46 analysis using inverse-variance weighted (IVW) regression to systematically infer the causal 47 effects of plasma TG levels on 2,600 disease traits in the European ancestry population of UK 48 Biobank. For replication, we externally tested 221 nominally significant associations (p < 0.05) 49 in an independent cohort from FinnGen. To account for potential horizontal pleiotropy and the 50 influence of invalid instrumental variables, we performed sensitivity analyses using MR-Egger 51 regression, weighted median estimator, and MR-PRESSO. Finally, we used multivariable MR 52 controlling for correlated lipid fractions to distinguish the independent effect of plasma TG 53 levels.

54

**Results:** Our results identified 7 disease traits reaching Bonferroni-corrected significance in both the discovery ( $p < 1.92 \times 10^{-5}$ ) and replication analyses ( $p < 2.26 \times 10^{-4}$ ), supporting a causal relationship between plasma TG levels and ASCVDs, including coronary artery disease (OR 1.33, 95% CI 1.24-1.43,  $p = 2.47 \times 10^{-13}$ ). We also identified 12 disease traits that were Bonferroni-significant in the discovery or replication analysis and at least nominally significant in the other analysis (p < 0.05), identifying plasma TG levels as a novel risk factor for 9 non-ASCVD diseases, including uterine leiomyoma (OR 1.19, 95% CI 1.10-1.29,  $p = 1.17 \times 10^{-5}$ ).

63	Conclusions: Taking a phenome-wide, two-sample MR approach, we identified causal
64	associations between plasma TG levels and 19 disease traits across organ systems. Our findings
65	suggest unrealized drug repurposing opportunities or adverse effects related to approved and
66	emerging TG-lowering agents as well as mechanistic insights for future study.
67	
68	Funding: RD is supported by the National Institute of General Medical Sciences of the National
69	Institutes of Health (NIH) (R35-GM124836) and the National Heart, Lung, and Blood Institute
70	of the NIH (R01-HL139865 and R01-HL155915).

# 71 Introduction

72	Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death
73	worldwide despite the effectiveness of statin therapy in reducing low-density lipoprotein
74	cholesterol (LDL-C) levels (Baigent et al., 2005) (Roth et al., 2020). Additional therapeutic
75	targets and adjunctive treatments are needed to address the burden arising from residual risk
76	(Rosenson & Goonewardena, 2021). Triglycerides (TG) play vital roles in physiology, ranging
77	from energy storage and mobilization to inflammation, thrombosis, and hormone-like signaling
78	(Zewinger et al., 2020) (Norata et al., 2007). However, a causal relationship between TGs and
79	ASCVDs remains controversial (Miller et al., 2011) (Albrink & Man, 1959), recently
80	culminating in the conflicting reports of two double-blinded randomized controlled trials (RCT),
81	STRENGTH and REDUCE-IT (Nicholls et al., 2020) (Bhatt et al., 2019) (Doi et al., 2021).
82	Nevertheless, drug development for reducing TG-rich lipoproteins (TRL) is an active area of
83	research and several targets have now been validated, including angiopoietin-like 3 (ANGPTL3)
84	(Graham et al., 2017) (Dewey et al., 2017) (Musunuru et al., 2010) (Gaudet et al., 2017),
85	angiopoietin-like 4 (ANGPTL4) (Dewey et al., 2016), and apolipoprotein C-III (APOC3)
86	(Gaudet et al., 2015) (Crosby et al., 2014). Clinical trials are currently evaluating these targets
87	for dyslipidemias (Arrowhead, 2021b) (Arrowhead, 2021a).
88	Whether TGs are causal risk factors or simply associative biomarkers remains uncertain
89	not only for ASCVDs but also other diseases of different organ systems. Understanding the
90	causal effects of TGs across a broader range of human diseases could have significant
91	implications for drug repurposing. TG-lowering agents, such as fibrates (Frick et al., 1987)
92	(Group, 2010) and omega-3 fatty acids (Bhatt et al., 2019) have already been approved; however,
93	not knowing which diseases are causally affected by TGs precludes their use for indications


94	other than hypertriglycidemia. Understanding the protective effects of TGs could also have
95	implications for drug safety. With the recent approval of icosapent ethyl (Bhatt et al., 2019)
96	(Gaba et al., 2022) and the ongoing development of other TG-lowering agents (Shaik &
97	Rosenson, 2021), such as ANGPTL3 (Graham et al., 2017) (Dewey et al., 2017), ANGPTL4, and
98	APOC3 inhibitors (Gaudet et al., 2015), long-term safety becomes a matter of concern. Post-
99	market surveillance data are limited; therefore, identifying diseases with negative causal links to
100	TGs could suggest adverse side effects, whereas protective causal links to TGs could suggest
101	therapeutic avenues and indices informative for drug development. Further, this could inform
102	polypharmacy and drug titration in clinical practice.
103	Several methodological challenges have prohibited causal conclusions about TGs across
104	human diseases. First, TGs are correlated with established ASCVD risk factors, such as obesity
105	and insulin resistance (Eckel et al., 2005). They also correlate with LDL particles or
106	apolipoprotein B (apoB) concentration (Cromwell et al., 2007) and inversely correlate with high-
107	density lipoprotein cholesterol (HDL-C) (Phillips & Smith, 1991). Conventional observational
108	studies have thus been limited in drawing causal inferences due to potential confounding.
109	Secondly, available TG-lowering agents have pleiotropic effects on several major lipid fractions,
110	including VLDL-C, LDL-C, HDL-C, and apolipoproteins, including APOC3 (Group, 2010)
111	(Keech et al., 2005) (Frick et al., 1987). Thus, costly RCTs have had limited power to
112	disentangle the effects of lowering TG specifically (Triglyceride Coronary Disease Genetics et
113	al., 2010) (Goldberg et al., 2011) (Bhatt et al., 2019). Finally, Mendelian randomization (MR)
114	studies have typically focused on individual diseases selected a priori (Davey Smith & Hemani,
115	2014), narrowing the scope of causal estimates to ASCVDs while overlooking non-ASCVD
116	diseases (Harrison et al., 2018) (Smith et al., 2014) (Allara et al., 2019).

117	Phenome-wide MR is a high-throughput extension of MR that, under specific
118	assumptions, estimates the causal effects of an exposure on multiple outcomes simultaneously.
119	As in conventional MR, this method uses genetic variants as instrumental variables (IV) to proxy
120	modifiable exposures while minimizing confounding (Davey Smith & Ebrahim, 2003). A
121	distinction, however, is that phenome-wide MR enables comprehensive scans of the phenotypic
122	spectrum, limiting bias from prior assumptions and facilitating the discovery of unforeseen
123	causal relationships. This has recently become feasible with the maturation of large-scale
124	biobanks providing extensive genetic and phenotypic data, such as the UK Biobank (UKB)
125	(Bycroft et al., 2018) and FinnGen project (FinnGen, 2020).
126	Here, we use phenome-wide MR to systematically estimate the causal effects of plasma
127	TGs on 2,600 disease outcomes in UKB, followed by replication testing in FinnGen. We then
128	apply multiple MR methods for sensitivity analyses and multivariable MR to control for plasma
129	LDL-C and HDL-C level.

# 130 Methods

#### 131 Study design and data sources

- 132 We followed the guidelines published by Burgess et al. (Burgess et al., 2020) and the
- 133 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines
- 134 (Skrivankova et al., 2021). Accordingly, we note that MR analyses rely on three important
- 135 instrumental variable assumptions: (1) the genetic variant is directly associated with the
- 136 exposure; (2) the genetic variant is unrelated to confounders between the exposure and outcome;
- 137 and (3) the genetic variant has no effect on the outcome other than through the exposure (Davey
- 138 Smith & Ebrahim, 2003). This study uses three non-overlapping genome-wide association
- 139 studies (GWAS). A schematic figure summarizes the study design (Fig 1).



## 140

#### 141 Fig 1. Study overview.

142 A schematic summarizing the study design. GLGC, Global Lipids Genetics Consortium; HDL, 143 high-density lipoprotein; IVW, inverse-variance weighted; LDL, low-density lipoprotein; MR, 144 Mendelian randomization; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum 145 and Outlier; SNP, single-nucleotide polymorphism; TG, triglyceride; UKB, UK Biobank. Tier 1 146 (BB): At least Bonferroni-significant in both the discovery and replication analyses. Tier 2 (BN): 147 At least Bonferroni-significant in the discovery analysis and at least nominally significant in the 148 replication analysis. Tier 3 (NB): At least nominally significant in the discovery analysis and at 149 least Bonferroni-significant in the replication analysis.

151	For primary and sensitivity analyses, we conducted two-sample MR taking summary
152	statistics for genetic associations with plasma TGs from one dataset (Global Lipids Genetics
153	Consortium, GLGC) (Willer et al., 2013) and summary statistics for genetic associations with
154	outcomes from a second, independent dataset (UKB). The CARDIoGRAMplusC4D Metabochip
155	study by GLGC involved 63,746 cases and 130,681 controls (Deloukas et al., 2013). UKB is a
156	longitudinal, population-based cohort study with genetic and phenotypic data on over 500,000
157	participants aged 40-69 years at recruitment from across the United Kingdom during 2006-2010
158	(Sudlow et al., 2015). The sociodemographic and health-related characteristics of UKB
159	participants have been described elsewhere (Fry et al., 2017).
160	For replication analysis, we again performed two-sample MR but used summary statistics
161	for TG from UKB and summary statistics for outcomes from FinnGen (Release 4; 176,899
162	samples; 169,962,023 variants). FinnGen is a large public-private partnership started in August
163	2017 aiming to collect and analyze genomic and phenotypic data from 500,000 Finnish biobank
164	participants (FinnGen, 2020) (Kurki et al., 2022). For both primary and replication analysis,
165	there is likely to be minimal sample overlap in the two-sample MR, which can cause weak-
166	instrument bias and inflated type 1 error (Burgess et al., 2016).
167	
168	Genetic instruments
169	For primary and secondary analyses, we identified 3,086 single nucleotide

170 polymorphisms (SNP) associated with plasma TG levels in GLGC at a genome-wide

171 significance threshold of  $p < 5 \times 10^{-8}$ . A total of 141 independent SNPs were then selected at a

172 linkage disequilibrium (LD) threshold of  $r^2 < 0.05$  using the 1000 Genomes LD European panel

173 as the reference population (Auton et al., 2015). To select independent SNPs, we used the

174	PLINK software's LD clumping command (Purcell et al., 2007) with the following options:
175	clump-p1 0.00000005clump-p2 0.0005clump-r2 0.05clump-kb 250.
176	For replication analysis, we identified 1,388 SNPs associated with plasma TG levels in
177	UKB after restricting for genome-wide significance ( $p < 5 \times 10^{-8}$ ) and LD-clumping. The SNPs
178	were selected at an LD threshold of $r^2 < 0.05$ using the 1000 Genomes LD European panel as the
179	reference population. LD clumping was performed by PLINK using the same command as
180	above. We then restricted to 1,248 SNPs for genetic instrumentation based on whether the SNP
181	was also available in the FinnGen dataset.

182

#### 183 Disease outcomes

184 As a phenome-wide investigation, this study examined many binary disease outcomes. 185 For outcomes of primary and sensitivity analyses, we used genome-wide association summary 186 statistics from the European ancestry subset of UKB. The focus on European ancestry was 187 needed to reduce heterogeneity and maximize statistical power. Pan-UKB performed 16,000 188 genome-wide association studies in ~500,000 UKB participants of various ancestries using 189 genetic and phenotypic data (PanUKBTeam, 2020). A total of 7,221 total phenotypes were 190 categorized as "biomarker", "continuous", "categorical", "ICD-10 code", "phecode", or 191 "prescription" (PanUKBTeam, 2020). We filtered for outcomes to retain categorical, ICD-10, 192 and phecode types; non-null heritability in European ancestry as estimated by Pan-UKB; and 193 relevance to disease, excluding medications. This yielded 2,600 traits for primary analysis. 194 For outcomes of replication analysis, we used genome-wide association summary 195 statistics from FinnGen. To allow for compatibility between UKB and FinnGen datasets, 196 phenotypes coded as FinnGen "endpoint IDs" were mapped to ICD-10 codes or phecodes

197	corresponding to the coding convention used by UKB. Categorical traits in UKB could not be
198	reliably mapped to FinnGen IDs, requiring us to omit categorical traits from replication analysis.
199	Of 2,444 available FinnGen outcomes, we ultimately selected 221 outcomes for replication
200	testing based on two conditions: (1) The outcome has an equivalent phenotype documented as an
201	ICD-10 code or phecode in UKB, which we had included in the discovery analysis, and (2) the
202	outcome was at least nominally significant ( $p < 0.05$ ) in the discovery analysis.
203	
204	Statistical analyses
205	Primary discovery analysis used the inverse-variance weighted (IVW) method of two-
206	sample MR over the more horizontal pleiotropy-robust MR-Egger regression method to
207	maximize statistical power (Burgess et al., 2013). To proxy TG, we selected the 141 TG-
208	associated SNPs from Pan-UKB identified above as instrumental variables in MR testing. All
209	SNPs were harmonized to match the effect and non-effect allele at each SNP. For replication
210	analyses, we conducted IVW tests using TG-associated SNPs from UKB as exposures and 221
211	traits at least nominally significant ( $p < 0.05$ ) in the discovery analysis as outcomes from
212	FinnGen. R (4.1.0) was used for all analyses (R Core Team, 2021).
213	For sensitivity analyses, we addressed the possible presence of horizontal pleiotropy by
214	applying MR-Egger (Bowden et al., 2015), weighted median estimator (Bowden et al., 2016),
215	and MR-PRESSO outlier tests (Verbanck et al., 2018) on Bonferroni-significant traits identified
216	in the primary analysis above. MR-PRESSO outlier tests were performed on 16 traits with
217	significant MR-PRESSO global test results ( $p < 0.05$ ). To account for potential horizontal
218	pleiotropy due to outliers, we examined the MR-PRESSO outlier test p-values from the
219	discovery analysis, and as recommended (Burgess et al., 2020), removed outlier IVs (between 1

220	and 10 SNPs for each outcome) based on a corrected significance threshold ( $p < 0.05 / 141 =$
221	$3.55 \times 10^{-4}$ ). IVW tests were then re-run without the outlier IVs in the discovery analysis.
222	Additionally, we fitted multivariable MR (MVMR) models controlling for plasma LDL-
223	C and HDL-C levels in the discovery stage. MVMR uses genetic variants associated with
224	multiple exposures to estimate the effect of each exposure on an outcome, thereby accounting for
225	potentially correlated exposures (Sanderson, 2021). We extracted the 141 LD-independent TG-
226	associated SNPs described above from the summary statistics for LDL and HDL provided by
227	GLGC. We then performed three MVMR IVW tests against traits Bonferroni-significant in our
228	discovery analysis with the following sets of exposures: TG and LDL; TG and HDL; or TG,
229	HDL, and LDL.
230	To account for multiple testing, a conservative Bonferroni threshold for statistical
231	significance was set to $p < 0.05 / 2600 = 1.92 \times 10^{-5}$ for the discovery analysis. For replication
232	analysis, a similar conservative Bonferroni threshold was set to $p < 0.05 / 221 = 2.26 \times 10^{-4}$ . We
233	determined three tiers of statistical evidence based on the Bonferroni or nominal threshold ( $p <$
234	0.05) in both the discovery and replication analyses. These three tiers are defined below:
235	1. Tier 1 (BB): At least Bonferroni-significant in both the discovery and replication analyses.
236	2. Tier 2 (BN): At least Bonferroni-significant in the discovery analysis and at least nominally
237	significant in the replication analysis.
238	3. Tier 3 (NB): At least nominally significant in the discovery analysis and at least Bonferroni-
239	significant in the replication analysis.
240	


241 Ethical approval

242	UK Biobank has approval from the North West Multi Centre Research Ethics Committee
243	(MREC) as a Research Tissue Bank (RTB) (11/NW/0382), and all participants of UKB provided
244	written informed consent. More information is available at (https://www.ukbiobank.ac.uk/learn-
245	more-about-uk-biobank/about-us/ethics). The work described in this study was approved by
246	UKB under application number 16218. All participants of FinnGen provided written informed
247	consent for biobank research, based on the Finnish Biobank Act. The Coordinating Ethics
248	Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study
249	protocol Nr HUS/990/2017. More information is available at
250	(https://www.finngen.fi/en/code_of_conduct).
251	
252	Data availability
253	All data generated in this study are included in the manuscript and supplementary tables.
254	All analyses used publicly available data (UKB, FinnGen), including previously published
255	GWAS (GLGC) (Willer et al., 2013). Obtaining access to UKB (PanUKBTeam, 2020) and
256	FinnGen (FinnGen, 2020) GWAS summary statistics is detailed here
257	(https://www.finngen.fi/en/access_results) and here (https://www.ukbiobank.ac.uk/enable-your-
258	research/apply-for-access). Please note the summary statistics for FinnGen and Pan-UKB are
259	made publicly available.


## 260 **Results**

#### 261 Genetically proxied plasma TG levels and phenome-wide disease risk

262 In the discovery analysis, we identified nominally significant associations (p < 0.05) 263 between plasma TG levels and 598 disease traits in UKB (S1 Table). Of these, 39 disease traits 264 were statistically significant after multiple testing correction with a conservative Bonferroni-265 corrected threshold ( $p < 1.92 \times 10^{-5}$ ). As a positive control, plasma TG levels were positively associated with gout with an odds ratio (OR) of 1.78 for gout (95% CI 1.52-2.09,  $p = 7.41 \times 10^{-10}$ 266 267 <sup>11</sup>). in agreement with prior studies (Yu et al., 2021). In the replication analysis, we identified 268 nominally significant associations (p < 0.05) between plasma TG levels and 71 disease traits in 269 FinnGen (S2 Table). Of these, 22 traits were Bonferroni-significant. A summary of the 19 most 270 statistically significant and replicated results have been organized into three predefined tiers of 271 evidence (Fig 2). We note that the magnitude of estimates from the discovery analysis were 272 generally greater than those from replication analysis, especially among tier 1 and tier 2 273 associations, potentially as a manifestation of winner's curse bias (Göring et al., 2001).



274



## 276 regression in UKB and FinnGen.

277 Causal estimates from inverse-variance weighted (IVW) regression are shown as odds ratios

- 278 (OR) per 1 SD increase in plasma triglyceride (TG) levels (mmol/L). Asterisks indicate novel
- 279 associations. Black indicates discovery analysis results using UKB. Red indicates replication
- analysis results using FinnGen. Horizontal lines represent 95% confidence intervals. Tier 1 (BB):

At least Bonferroni-significant in both the discovery and replication analyses. Tier 2 (BN): At least Bonferroni-significant in the discovery analysis and at least nominally significant in the replication analysis. Tier 3 (NB): At least nominally significant in the discovery analysis and at least Bonferroni-significant in the replication analysis. Full results are provided in S1 and S2 Tables.

286


287 For tier 1 results, genetically determined plasma TG levels were positively associated 288 with 7 disease traits in both the discovery and replication analyses. These were Bonferroni-289 significant in both analyses, and all were related to dyslipidemias or ASCVD. Among traits 290 related to ASCVD, the strongest association by statistical significance was for angina pectoris in 291 both the discovery UKB cohort (OR 1.39, 95% CI 1.29-1.51,  $p = 2.11 \times 10^{-13}$ ) and the replication FinnGen cohort (OR 1.30, 95% CI 1.24-1.37,  $p = 1.25 \times 10^{-26}$ ). For tier 2 results, plasma TG 292 293 levels were positively associated with 3 disease traits, including non-ASCVDs: gout, uterine 294 leiomyoma, and "other aneurysms" (phecode-442). The strongest association by significance, 295 after gout, was for leiomyoma of the uterus in both the discovery (OR 1.19, 95% CI 1.10-1.29, p =  $1.17 \times 10^{-5}$ ) and replication cohorts (OR 1.06, 95% CI 1.02-1.11,  $p = 3.60 \times 10^{-3}$ ). For tier 3 296 297 results, 9 disease traits were identified, and a greater proportion were non-ASCVD traits. The 298 strongest association by significance was for hypertension in both the discovery (OR 1.51, 95%) CI 1.08-1.23,  $p = 3.20 \times 10^{-5}$ ) and replication cohorts (OR 1.17, 95% CI 1.14-1.22,  $p = 9.49 \times 10^{-5}$ ) 299 10-20). 300

301

302

#### 304 Sensitivity analyses using MR-PRESSO, MR-Egger, and Weighted Median methods

305 To account for potential horizontal pleiotropy bias due to outlier IVs, we next used the 306 MR-PRESSO test on the 19 significant and replicated associations identified above, which were 307 categorized into three tiers of statistical evidence. MR-PRESSO suspected outlier IVs for 16 of 308 the 19 associations, and between 1 and 10 IVs were identified for 8 associations (S3 Table). We 309 then re-ran IVW MR for these 8 associations after removing outlier IVs (S3 Table). Among tier 310 1 results, all 7 associations increased in significance after outlier removal (Fig 3). For tier 2 311 results, two of three associations had significant global MR-PRESSO test values but no outlier 312 IVs were removed. For tier 3 results, seven of nine associations had significant global MR-313 PRESSO test values, and outlier IVs were removed for one of these associations (S3 Table), which increased in significance: hypertension ( $p = 3.20 \times 10^{-5}$  to  $p = 2.80 \times 10^{-8}$ ). Importantly, 314 315 all associations maintained the same effect direction after the MR-PRESSO outlier test, in 316 keeping with the initial discovery analysis.



#### 317


#### 318 Fig 3. Causal estimates of genetically proxied plasma TG levels on disease risk using MR-

#### 319 Egger, Weighted Median, and MR-PRESSO methods in UKB.


320 Shown are sensitivity analysis results from the discovery stage using instruments from GLGC

- 321 and outcomes from UKB. Levels of statistical significance are expressed as  $-\log_{10}(p)$  values.
- 322 Associations with insignificant global MR-PRESSO test results (p > 0.05) were not rerun and do
- 323 not have data points for IVW after MR-PRESSO. Tier 1 (BB): At least Bonferroni-significant in

324	both the discovery and replication analyses. Tier 2 (BN): At least Bonferroni-significant in the
325	discovery analysis and at least nominally significant in the replication analysis. Tier 3 (NB): At
326	least nominally significant in the discovery analysis and at least Bonferroni-significant in the
327	replication analysis. Full results are found in S1 and S3 Tables.
328	
329	To further account for horizontal pleiotropy, we conducted sensitivity analyses for the 19
330	significant and replicated traits using the MR-Egger and weighted median estimators on UKB
331	data (Fig 3). MR-Egger results were comparable to IVW results for all 19 traits across the three
332	tiers of evidence. However, weighted median results were less statistically significant than IVW
333	and MR-Egger results for most traits except for disorders of lipid metabolism, hyperlipidemia,
334	and hypertension.
335	
336	Separating the independent effects of plasma TG levels
337	To isolate the independent effect of plasma TG levels from those of correlated lipid
338	fractions, we next conducted multivariable MR (MVMR) on the 19 significant and replicated
339	associations using the IVW estimator on UKB data, adjusting for plasma HDL-C, LDL-C, or
340	both simultaneously (Fig 4). For tier 1 associations, we observed an increase in statistical
341	significance for disorders of lipid metabolism and hyperlipidemia after adjustment. For tier 2
342	results, we observed an increase in significance for gout. For tier 3 results, we observed an
343	increase in significance for alcoholic liver disease, paroxysmal tachycardia, and calculus of
344	kidney and ureter. Aside from these, MVMR led to a decrease in statistical significance for the
345	remaining associations. However, all 19 associations remained in the same direction of causality
346	despite multivariable adjustment (S4 Table).







#### 349 multivariable IVW regression controlling for plasma LDL-C and HDL-C levels in UKB.

- 350 Shown are the multivariable MR results from the discovery analysis, using genetic instruments
- 351 for plasma TG levels from GLGC and disease traits from UKB. Degrees of statistical
- 352 significance are categorized into three tiers: Tier 1 (BB): At least Bonferroni-significant in both
- 353 the discovery and replication analyses. Tier 2 (BN): At least Bonferroni-significant in the

- 354 discovery analysis and at least nominally significant in the replication analysis. Tier 3 (NB): At
- 355 least nominally significant in the discovery analysis and at least Bonferroni-significant in the
- 356 replication analysis. Full results are provided in S4 Table.

# 357 **Discussion**

358	We performed phenome-wide, two-sample MR to estimate the causal effects of plasma
359	TG levels on a spectrum of human disease traits ( $n = 2,600$ ) using a discovery cohort from UKB
360	and a replication cohort from FinnGen. We report 7 disease traits reaching Bonferroni-corrected
361	significance in both the discovery and replication analyses, which we categorized as tier 1
362	results. These traits were predominantly manifestations of ASCVD, such as ischemic heart
363	disease, angina pectoris, and myocardial infarction. Using multivariable MR, we found that these
364	associations remained even after controlling for LDL-C and HDL-C (Fig 4). We also identified 3
365	disease traits that are both Bonferroni-significant in the discovery analysis ( $p < 1.92 \times 10^{-5}$ ) and
366	at least nominally significant in the replication analysis ( $p < 0.05$ ), categorized as tier 2 results.
367	Lastly, we identified 9 disease traits at least nominally significant in the discovery analysis and
368	Bonferroni-significant in replication analysis, categorized as tier 3 results. Several of these
369	disease traits have never been reported to be causally associated with TGs, introducing new
370	opportunities for drug repurposing and further mechanistic studies.
371	Our results are consistent with prior work suggesting that plasma TG levels are causally
372	associated with ASCVD risk (Triglyceride Coronary Disease Genetics et al., 2010) (Castañer et
373	al., 2020) (Do et al., 2013) (Dewey et al., 2016) (Holmes et al., 2015) (White et al., 2016) (Varbo
374	et al., 2013) (Ibi et al., 2021) (Rosenson et al., 2021). We do not prove here that circulating TGs
375	per se are directly atherogenic; rather, we show that plasma TG measurement, which comprises
376	multiple classes of triglyceride-rich lipoproteins (TRL) and their remnants, captures a clinically
377	significant mechanism that is causally associated with ASCVD (Rosenson et al., 2021). This
378	interpretation is concordant with the emerging consensus that apolipoprotein B (apoB) particle
379	number is a more important determinant of atherogenesis than LDL-C and that TRL particles are

380	as important a risk factor in ASCVD as LDL particles, since they both carry a single apoB
381	
301	molecule (Ference et al., 2019) (Marston et al., 2021) (Richardson et al., 2020). According to this
382	paradigm, the causal association we observe between plasma TG levels and ASCVD risk may be
383	mediated by the concentration of apoB particles in TRLs, captured by plasma TG level
384	measurements. If reducing TRLs proportionally reduces apoB levels (Ference et al., 2019), these
385	results support that lowering plasma TG levels could serve as a valid therapeutic strategy to
386	reducing ASCVD risk. Additional studies controlling for apoB are needed to test whether
387	decreasing plasma TGs without a concomitant decrease in apoB could reduce ASCVD risk by
388	alternative mechanisms unrelated to apoB.
389	Regarding non-ASCVDs, we show novel causal associations between plasma TG levels
390	and uterine leiomyomas (uterine fibroids), diverticular disease of intestine, paroxysmal
391	tachycardia, hemorrhage from respiratory passages (hemoptysis), and calculus of kidney and
392	ureter (kidney stones). Prior studies had reported correlational associations between many of
393	these diseases and plasma TG levels or risk factors correlated to plasma TGs. For example,
394	studies had documented positive correlations between leiomyoma risk and plasma TG levels
395	(Uimari et al., 2016) (Tonoyan et al., 2021) (Peshkova et al., 2020). Others had shown
396	diverticular disease risk is positively associated with BMI, body fat percentage, and visceral fat
397	area (Shih et al., 2022) (Freckelton et al., 2018) (Böhm, 2021). Similarly, kidney stones have
398	been associated with the triglyceride-glucose (TyG) index (Qin et al., 2021), and atrial
399	tachycardias have been associated with VLDL levels in metabolic syndrome patients (Lee et al.,
400	2017) (Park & Lee, 2018). Our study is the first to suggest that these associations may be
401	causally related and specific to plasma TG levels, as opposed to or in addition to confounding
402	risk factors, such as obesity and hormone replacement therapy. We thus present rationale for

403 repurposing TG-lowering agents towards these diseases and pursuing mechanistic studies 404 interrogating TG biology; however, RCTs are necessary to better evaluate clinical potential. 405 Our results also identified a novel, negative causal association between plasma TG levels 406 and alcoholic liver disease (ALD), suggesting that excessively reducing plasma TG levels may 407 increase risk of this disease trait. A mechanistic explanation for this association remains elusive 408 as previous studies on dysregulated lipid metabolism in liver disease have generally focused on 409 non-alcoholic fatty liver disease (NAFLD). However, one animal study suggests that medium-410 chain TGs may decrease lipid peroxidation and reverse established alcoholic liver injury in rat 411 models of ALD (Nanji et al., 1996). Nevertheless, that elevated TG levels may protect against 412 ALD is surprising and requires validation. It remains unclear whether this association is only 413 relevant to lifelong, chronic lowering of plasma TG levels rather than transient lowering by drug-414 based interventions. It is also unclear whether ALD could be prevented by increasing TG levels. 415 Our finding emphasizes the potential intolerability of TG-lowering agents and the importance of 416 maintaining these drugs' concentrations within therapeutic windows for patient safety. 417 This study has several limitations. First, horizontal pleiotropy has been shown to be 418 common in genetic variation, which can cause bias in MR testing (Verbanck et al., 2018) (Jordan 419 et al., 2019). We used MR tests that are robust to horizontal pleiotropy including the MR-420 PRESSO test as well as MR-Egger and weighted median estimators as sensitivity analyses. 421 Second, genetic variants confer exposures that are lifelong but small in effect size; thus, MR may 422 over- or underestimate the effect sizes of pharmacological interventions. MR also cannot make 423 comparisons between TG-lowering agents as it evaluates drug targets, not drug subclasses and 424 unique pharmacodynamics (Gill et al., 2019) (Sofat et al., 2010). However, the utility of MR in 425 drug target validation is well-established as estimates still indicate the presence and direction of

426 causality (Gill et al., 2021). Third, we were unable to reliably map "categorical" traits from UKB 427 to corresponding traits in FinnGen for all traits, testing for replication only 221 of the 598 428 associations that were nominally significant in the primary analysis. Moreover, ICD-10 codes 429 and phecodes are imperfect descriptors of disease, liable to misclassification. Lastly, we 430 acknowledge that this study was restricted to populations of European ancestry, limiting the 431 generalizability of our findings. A recent study observed comparable MR estimates for the causal 432 effects of lipid traits on ischemic stroke risk between African and European ancestry individuals 433 (Fatumo et al., 2021), suggesting the potential generalizability of MR results across ancestries in 434 some specific cases. Nevertheless, trans-ancestry MR analyses are warranted to validate our 435 study's findings in diverse ancestry populations. 436 In conclusion, this study demonstrates a high-throughput application of two-sample MR 437 to estimate the causal effects of plasma TGs on disease risk phenome-wide. With the 438 proliferation of multiomic data, this systematic approach could be generalized to study the causal 439 effects of serum biomarkers at scale to support the prioritization of targets for drug discovery. 440 Further studies are needed however to consider the functional and qualitative attributes of TRL 441 and TG subtypes. Metabolomic data partitioning TRLs by size and composition may enable this 442 to identify the subcomponent of a plasma TG measurement that drives disease risk (Holmes et 443 al., 2015). Diverse study designs are warranted to further triangulate evidence for the causal 444 effects of plasma TG levels on disease risk. 445

## 446 Acknowledgements

447 We acknowledge the participants and investigators of the FinnGen and UKB studies.

# 449 **Competing interests**

- 450 RD reports receiving grants from AstraZeneca; grants and non-financial support from Goldfinch
- 451 Bio; being a scientific co-founder, consultant, and equity holder (pending) for Pensieve Health;
- 452 and a consultant for Variant Bio, all unrelated to this work. RSR reports receiving grants from
- 453 Amgen, Arrowhead, Lilly, Novartis and Regeneron; consulting fees from Amgen, Arrowhead,
- 454 Lilly, Novartis and Regeneron; honoraria for non-promotional lectures from Amgen, Kowa and
- 455 Regeneron, royalties from Wolters Kluwer (UpToDate); and stock holdings in MediMergent,
- 456 LLC.

# 457 **References**

- 458 Albrink, M. J., & Man, E. B. (1959). Serum Triglycerides in Coronary Artery Disease. A.M.A.
- 459 *Archives of Internal Medicine*, *103*(1), 4-8.
- 460 https://doi.org/10.1001/archinte.1959.00270010010002
- 461 Allara, E., Morani, G., Carter, P., Gkatzionis, A., Zuber, V., Foley, C. N., Rees, J. M. B., Mason,
- 462 A. M., Bell, S., Gill, D., Lindström, S., Butterworth, A. S., Angelantonio, E. D., Peters,
- 463 J., & Burgess, S. (2019). Genetic Determinants of Lipids and Cardiovascular Disease
- 464 Outcomes. *Circulation: Genomic and Precision Medicine*, *12*(12), e002711.
- 465 <u>https://doi.org/doi:10.1161/CIRCGEN.119.002711</u>
- 466 Arrowhead. (2021a). Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2). U.S.
- 467 National Library of Medicine. <u>https://clinicaltrials.gov/ct2/show/NCT04832971</u>
- 468 Arrowhead. (2021b). Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR). U.S.
- 469 National Library of Medicine. <u>https://clinicaltrials.gov/ct2/show/NCT04998201</u>
- 470 Auton, A., Abecasis, G. R., Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R.,
- 471 Chakravarti, A., Clark, A. G., Donnelly, P., Eichler, E. E., Flicek, P., Gabriel, S. B.,
- 472 Gibbs, R. A., Green, E. D., Hurles, M. E., Knoppers, B. M., Korbel, J. O., Lander, E. S.,
- 473 Lee, C., . . . Abecasis, G. R. (2015). A global reference for human genetic variation.
- 474 *Nature*, *526*(7571), 68-74. <u>https://doi.org/10.1038/nature15393</u>
- 475 Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A.,
- 476 Sourjina, T., Peto, R., Collins, R., & Simes, R. (2005). Efficacy and safety of cholesterol-
- 477 lowering treatment: prospective meta-analysis of data from 90,056 participants in 14
- 478 randomised trials of statins. *Lancet (London, England)*, *366*(9493), 1267-1278.
- 479 <u>https://doi.org/10.1016/s0140-6736(05)67394-1</u>

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R.

481	T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, JC., & Ballantyne, C. M. (2019).
482	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New
483	England Journal of Medicine, 380(1), 11-22. https://doi.org/10.1056/nejmoa1812792
484	Böhm, S. K. (2021). Excessive Body Weight and Diverticular Disease. Visc Med, 37(5), 372-
485	382. <u>https://doi.org/10.1159/000518674</u>
486	Bowden, J., Davey Smith, G., & Burgess, S. (2015). Mendelian randomization with invalid
487	instruments: effect estimation and bias detection through Egger regression. International
488	Journal of Epidemiology, 44(2), 512-525. https://doi.org/10.1093/ije/dyv080
489	Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016). Consistent Estimation in
490	Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
491	Estimator. Genetic Epidemiology, 40(4), 304-314. https://doi.org/10.1002/gepi.21965
492	Burgess, S., Butterworth, A., & Thompson, S. G. (2013). Mendelian Randomization Analysis
493	With Multiple Genetic Variants Using Summarized Data. Genetic Epidemiology, 37(7),
494	658-665. https://doi.org/10.1002/gepi.21758
495	Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig,
496	F. P., Holmes, M. V., Minelli, C., Relton, C. L., & Theodoratou, E. (2020). Guidelines
497	for performing Mendelian randomization investigations. Wellcome open research, 4, 186.
498	https://doi.org/10.12688/wellcomeopenres.15555.2
499	Burgess, S., Davies, N. M., & Thompson, S. G. (2016). Bias due to participant overlap in two-
500	sample Mendelian randomization. Genet Epidemiol, 40(7), 597-608.
501	https://doi.org/10.1002/gepi.21998

- 502 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic,
- 503 D., Delaneau, O., O'Connell, J., Cortes, A., Welsh, S., Young, A., Effingham, M.,
- 504 McVean, G., Leslie, S., Allen, N., Donnelly, P., & Marchini, J. (2018). The UK Biobank
- resource with deep phenotyping and genomic data. *Nature*, *562*(7726), 203-209.
- 506 <u>https://doi.org/10.1038/s41586-018-0579-z</u>
- 507 Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M.,
- 508 Corella, D., Salas-Salvadó, J., Estruch, R., Lapetra, J., Gómez-Gracia, E., Alonso-Gomez,
- 509 A. M., Fiol, M., Serra-Majem, L., Corbella, E., Benaiges, D., Sorli, J. V., Ruiz-Canela,
- 510 M., ... Fitó, M. (2020). Remnant Cholesterol, Not LDL Cholesterol, Is Associated With
- 511 Incident Cardiovascular Disease. J Am Coll Cardiol, 76(23), 2712-2724.
- 512 <u>https://doi.org/10.1016/j.jacc.2020.10.008</u>
- 513 Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., Sullivan, L., Vasan, R. S., Wilson,
- 514 P. W., & D'Agostino, R. B. (2007). LDL Particle Number and Risk of Future
- 515 Cardiovascular Disease in the Framingham Offspring Study Implications for LDL
- 516 Management. J Clin Lipidol, 1(6), 583-592. <u>https://doi.org/10.1016/j.jacl.2007.10.001</u>
- 517 Crosby, J., Peloso, G. M., Auer, P. L., Crosslin, D. R., Stitziel, N. O., Lange, L. A., Lu, Y., Tang,
- 518 Z. Z., Zhang, H., Hindy, G., Masca, N., Stirrups, K., Kanoni, S., Do, R., Jun, G., Hu, Y.,
- 519 Kang, H. M., Xue, C., Goel, A., . . . Kathiresan, S. (2014). Loss-of-function mutations in
- 520 APOC3, triglycerides, and coronary disease. *N Engl J Med*, *371*(1), 22-31.
- 521 <u>https://doi.org/10.1056/NEJMoa1307095</u>
- 522 Davey Smith, G., & Ebrahim, S. (2003). 'Mendelian randomization': can genetic epidemiology
- 523 contribute to understanding environmental determinants of disease?\*. *International*
- 524 *Journal of Epidemiology*, *32*(1), 1-22. <u>https://doi.org/10.1093/ije/dyg070</u>

525	Davey Smith.	G., & Heman	. G. (2014).	. Mendelian r	andomization:	genetic anchors	for causal
-----	--------------	-------------	--------------	---------------	---------------	-----------------	------------

- 526 inference in epidemiological studies. *Human molecular genetics*, 23(R1), R89-R98.
- 527 <u>https://doi.org/10.1093/hmg/ddu328</u>
- 528 Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., Thompson, J. R.,
- 529 Ingelsson, E., Saleheen, D., Erdmann, J., Goldstein, B. A., Stirrups, K., König, I. R.,
- 530 Cazier, J. B., Johansson, A., Hall, A. S., Lee, J. Y., Willer, C. J., Chambers, J. C., Esko,
- 531 T., ... Samani, N. J. (2013). Large-scale association analysis identifies new risk loci for
- 532 coronary artery disease. *Nat Genet*, 45(1), 25-33. <u>https://doi.org/10.1038/ng.2480</u>
- 533 Dewey, F. E., Gusarova, V., Dunbar, R. L., O'Dushlaine, C., Schurmann, C., Gottesman, O.,
- 534 McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., Leader, J. B., Murray, M. F.,
- 535 Ritchie, M. D., Kirchner, H. L., Habegger, L., Lopez, A., Penn, J., Zhao, A., Shao, W., . .
- 536 . Baras, A. (2017). Genetic and Pharmacologic Inactivation of ANGPTL3 and
- 537 Cardiovascular Disease. *N Engl J Med*, *377*(3), 211-221.
- 538 <u>https://doi.org/10.1056/NEJMoa1612790</u>
- 539 Dewey, F. E., Gusarova, V., O'Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C.
- 540 V., Habegger, L., Buckler, D., Lai, K.-M. V., Leader, J. B., Murray, M. F., Ritchie, M.
- 541 D., Kirchner, H. L., Ledbetter, D. H., Penn, J., Lopez, A., Borecki, I. B., Overton, J. D., .
- 542 . . Shuldiner, A. R. (2016). Inactivating Variants in ANGPTL4 and Risk of Coronary
- 543 Artery Disease. *New England Journal of Medicine*, *374*(12), 1123-1133.
- 544 <u>https://doi.org/10.1056/nejmoa1510926</u>
- 545 Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S.,
- 546 Kanoni, S., Ganna, A., Chen, J., Buchkovich, M. L., Mora, S., Beckmann, J. S., Bragg-
- 547 Gresham, J. L., Chang, H. Y., Demirkan, A., Den Hertog, H. M., Donnelly, L. A., Ehret,

548	G. B., Kathiresan, S. (2013). Common variants associated with plasma triglycerides
549	and risk for coronary artery disease. Nat Genet, 45(11), 1345-1352.

- 550 <u>https://doi.org/10.1038/ng.2795</u>
- 551 Doi, T., Langsted, A., & Nordestgaard, B. G. (2021). A possible explanation for the contrasting
- 552 results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. *European*
- 553 *Heart Journal*, 42(47), 4807-4817. <u>https://doi.org/10.1093/eurheartj/ehab555</u>
- 554 Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. *The Lancet*,

555 *365*(9468), 1415-1428. <u>https://doi.org/https://doi.org/10.1016/S0140-6736(05)66378-7</u>

- 556 Fatumo, S., Karhunen, V., Chikowore, T., Sounkou, T., Udosen, B., Ezenwa, C., Nakabuye, M.,
- 557 Soremekun, O., Daghlas, I., Ryan, D. K., Taylor, A., Mason, A. M., Damrauer, S. M.,
- 558 Vujkovic, M., Keene, K. L., Fornage, M., Järvelin, M.-R., Burgess, S., & Gill, D. (2021).
- 559 Metabolic Traits and Stroke Risk in Individuals of African Ancestry: Mendelian
- 560 Randomization Analysis. *Stroke*, *52*(8), 2680-2684.
- 561 <u>https://doi.org/doi:10.1161/STROKEAHA.121.034747</u>
- 562 Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J.,
- 563 Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E.,
- 564 Danesh, J., Nicholls, S. J., Bhatt, D. L., Sabatine, M. S., & Catapano, A. L. (2019).
- 565 Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR
- 566 Variants With Risk of Coronary Heart Disease. *JAMA*, *321*(4), 364-373.
- 567 <u>https://doi.org/10.1001/jama.2018.20045</u>
- 568 FinnGen. (2020). FinnGen Documentation of R4 Release
- 569 <u>https://finngen.gitbook.io/documentation/</u>

- 570 Freckelton, J., Holt, D., Borsaru, A., Gwini, S., Croagh, D., & Moore, G. (2018). The role of
- 571 body composition in diverticular disease. *Int J Colorectal Dis*, *33*(9), 1299-1302.
- 572 <u>https://doi.org/10.1007/s00384-018-3058-y</u>
- 573 Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K.,
- 574 Kaitaniemi, P., Koskinen, P., Manninen, V., Mäenpää, H., Mälkönen, M., Mänttäri, M.,
- 575 Norola, S., Pasternack, A., Pikkarainen, J., Romo, M., Sjöblom, T., & Nikkilä, E. A.
- 576 (1987). Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-
- 577 Aged Men with Dyslipidemia. *New England Journal of Medicine*, *317*(20), 1237-1245.
- 578 <u>https://doi.org/10.1056/NEJM198711123172001</u>
- 579 Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., &
- 580 Allen, N. E. (2017). Comparison of Sociodemographic and Health-Related
- 581 Characteristics of UK Biobank Participants With Those of the General Population.
- 582 *American Journal of Epidemiology*, *186*(9), 1026-1034.
- 583 <u>https://doi.org/10.1093/aje/kwx246</u>
- 584 Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B.,
- 585 Juliano, R. A., Jiao, L., Doyle, R. T., Granowitz, C., Tardif, J.-C., Giugliano, R. P.,
- 586 Martens, F. M. A. C., Gibson, C. M., & Ballantyne, C. M. (2022). Prevention of
- 587 Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With
- 588 Prior Myocardial Infarction. Journal of the American College of Cardiology, 79(17),
- 589 1660-1671. <u>https://doi.org/https://doi.org/10.1016/j.jacc.2022.02.035</u>
- 590 Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R.
- 591 S., Hughes, S. G., Viney, N. J., Graham, M. J., Crooke, R. M., Witztum, J. L., Brunzell,
- 592 J. D., & Kastelein, J. J. (2015). Antisense Inhibition of Apolipoprotein C-III in Patients

593 with Hypertriglyceridemia. *N Engl J Med*, *373*(5), 438-447.

594 <u>https://doi.org/10.1056/NEJMoa1400283</u>

- 595 Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K. Y., Sasiela, W.
- 596 J., Chan, K. C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl,
- 597 N., Yancopoulos, G. D., & Hovingh, G. K. (2017). ANGPTL3 Inhibition in Homozygous
- 598 Familial Hypercholesterolemia. *N Engl J Med*, 377(3), 296-297.

599 <u>https://doi.org/10.1056/NEJMc1705994</u>

- 600 Gill, D., Georgakis, M. K., Koskeridis, F., Jiang, L., Feng, Q., Wei, W.-Q., Theodoratou, E.,
- 601 Elliott, P., Denny, J. C., Malik, R., Evangelou, E., Dehghan, A., Dichgans, M., &
- 602Tzoulaki, I. (2019). Use of Genetic Variants Related to Antihypertensive Drugs to Inform

on Efficacy and Side Effects. *Circulation*, *140*(4), 270-279.

- 604 https://doi.org/10.1161/circulationaha.118.038814
- 605 Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan,
- 606 C., Hingorani, A. D., Howson, J. M. M., Burgess, S., Swerdlow, D. I., Davey Smith, G.,
- 607 Holmes, M. V., Dichgans, M., Scott, R. A., Zheng, J., Psaty, B. M., & Davies, N. M.
- 608 (2021). Mendelian randomization for studying the effects of perturbing drug targets.
- 609 *Wellcome open research*, 6, 16-16. <u>https://doi.org/10.12688/wellcomeopenres.16544.2</u>
- 610 Goldberg, I. J., Eckel, R. H., & McPherson, R. (2011). Triglycerides and heart disease: still a
- 611 hypothesis? *Arteriosclerosis, thrombosis, and vascular biology*, *31*(8), 1716-1725.
- 612 <u>https://doi.org/10.1161/ATVBAHA.111.226100</u>
- 613 Göring, H. H., Terwilliger, J. D., & Blangero, J. (2001). Large upward bias in estimation of
- 614 locus-specific effects from genomewide scans. American journal of human genetics,
- 615 69(6), 1357-1369. https://doi.org/10.1086/324471

- 616 Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E.,
- 617 McEvoy, B. W., Baker, B. F., Pham, N. C., Digenio, A., Hughes, S. G., Geary, R. S.,
- 618 Witztum, J. L., Crooke, R. M., & Tsimikas, S. (2017). Cardiovascular and Metabolic
- 619 Effects of ANGPTL3 Antisense Oligonucleotides. *New England Journal of Medicine*,
- 620 377(3), 222-232. https://doi.org/10.1056/NEJMoa1701329
- Group, T. A. S. (2010). Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *New England Journal of Medicine*, *362*(17), 1563-1574.
- 623 https://doi.org/10.1056/NEJMoa1001282
- Harrison, S. C., Holmes, M. V., Burgess, S., Asselbergs, F. W., Jones, G. T., Baas, A. F., van 't
- 625 Hof, F. N., de Bakker, P. I. W., Blankensteijn, J. D., Powell, J. T., Saratzis, A., de Borst,
- 626 G. J., Swerdlow, D. I., van der Graaf, Y., van Rij, A. M., Carey, D. J., Elmore, J. R.,
- 627 Tromp, G., Kuivaniemi, H., . . . Humphries, S. E. (2018). Genetic Association of Lipids
- 628 and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. JAMA

629 *cardiology*, *3*(1), 26-33. <u>https://doi.org/10.1001/jamacardio.2017.4293</u>

- 630 Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P.,
- 631 Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., Tragante, V., van Iperen, E. P.,
- 632 Sivapalaratnam, S., Shah, S., Elbers, C. C., Shah, T., Engmann, J., Giambartolomei, C.,
- 633 White, J., . . . Casas, J. P. (2015). Mendelian randomization of blood lipids for coronary
- 634 heart disease. *Eur Heart J*, *36*(9), 539-550. <u>https://doi.org/10.1093/eurheartj/eht571</u>
- 635 Ibi, D., Blauw, L. L., Noordam, R., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R.,
- 636 Christodoulides, C., Neville, M. J., Koivula, R., Rensen, P. C. N., Karpe, F., & van Dijk,
- 637 K. W. (2021). Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles

- 638 are associated with an additively improved lipoprotein profile. *Atherosclerosis*, 328, 144-
- 639 152. https://doi.org/10.1016/j.atherosclerosis.2021.04.015
- 640 Jordan, D. M., Verbanck, M., & Do, R. (2019). HOPS: a quantitative score reveals pervasive
- 641 horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of
- 642 human traits and diseases. *Genome Biol*, 20(1), 222. <u>https://doi.org/10.1186/s13059-019-</u>
- 643 <u>1844-7</u>
- 644 Keech, A., Simes, R. J., Barter, P., Best, J., Scott, R., Taskinen, M. R., Forder, P., Pillai, A.,
- 645 Davis, T., Glasziou, P., Drury, P., Kesäniemi, Y. A., Sullivan, D., Hunt, D., Colman, P.,
- 646 d'Emden, M., Whiting, M., Ehnholm, C., & Laakso, M. (2005). Effects of long-term
- 647 fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus
- 648 (the FIELD study): randomised controlled trial. *Lancet (London, England)*, *366*(9500),

649 1849-1861. <u>https://doi.org/10.1016/s0140-6736(05)67667-2</u>

- 650 Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K., Reeve, M. P.,
- 651 Laivuori, H., Aavikko, M., Kaunisto, M. A., Loukola, A., Lahtela, E., Mattsson, H.,
- Laiho, P., Della Briotta Parolo, P., Lehisto, A., Kanai, M., Mars, N., Rämö, J., ...
- Palotie, A. (2022). FinnGen: Unique genetic insights from combining isolated population
  and national health register data. *medRxiv*, 2022.2003.2003.22271360.
- 655 https://doi.org/10.1101/2022.03.03.22271360
- 656 Lee, H. C., Chen, C. C., Tsai, W. C., Lin, H. T., Shiao, Y. L., Sheu, S. H., Wu, B. N., Chen, C.
- 657 H., & Lai, W. T. (2017). Very-Low-Density Lipoprotein of Metabolic Syndrome
- 658 Modulates Gap Junctions and Slows Cardiac Conduction. *Sci Rep*, 7(1), 12050.
- 659 <u>https://doi.org/10.1038/s41598-017-11416-5</u>

660	Marston, N. A.	Giugliano, I	R. P., Melloni.	G. E. M., Park, J	G., Morrill, V	V., Blazing, M. A.,

- 661 Ference, B., Stein, E., Stroes, E. S., Braunwald, E., Ellinor, P. T., Lubitz, S. A., Ruff, C.
- 662 T., & Sabatine, M. S. (2021). Association of Apolipoprotein B–Containing Lipoproteins
- and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis:
- 664 Distinguishing Between Particle Concentration, Type, and Content. *JAMA cardiology*.
- 665 https://doi.org/10.1001/jamacardio.2021.5083
- 666 Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A.
- 667 C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., Lennie, T. A., Levi, M.,
- 668 Mazzone, T., & Pennathur, S. (2011). Triglycerides and Cardiovascular Disease.
- 669 *Circulation*, *123*(20), 2292-2333. <u>https://doi.org/doi:10.1161/CIR.0b013e3182160726</u>
- 670 Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K.
- 671 V., Fisher, S., Abreu, J., Barry, A. J., Fennell, T., Banks, E., Ambrogio, L., Cibulskis, K.,
- 672 Kernytsky, A., Gonzalez, E., Rudzicz, N., Engert, J. C., DePristo, M. A., . . . Kathiresan,
- 673 S. (2010). Exome sequencing, ANGPTL3 mutations, and familial combined
- 674 hypolipidemia. *N Engl J Med*, *363*(23), 2220-2227.
- 675 <u>https://doi.org/10.1056/NEJMoa1002926</u>
- 676 Nanji, A. A., Yang, E. K., Fogt, F., Sadrzadeh, S. M., & Dannenberg, A. J. (1996). Medium

677 chain triglycerides and vitamin E reduce the severity of established experimental

- 678 alcoholic liver disease. Journal of Pharmacology and Experimental Therapeutics, 277(3),
- 679 1694-1700. <u>https://jpet.aspetjournals.org/content/jpet/277/3/1694.full.pdf</u>
- 680 Nicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson,
- 681 M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., Ridker, P. M.,
- 682 Ray, K. K., Katona, B. G., Himmelmann, A., Loss, L. E., Rensfeldt, M., Lundström, T.,

683	Agrawal, R., Nissen, S. E. (2020). Effect of High-Dose Omega-3 Fatty Acids vs Corn
684	Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk.
685	JAMA, 324(22), 2268. https://doi.org/10.1001/jama.2020.22258
686	Norata, G. D., Grigore, L., Raselli, S., Redaelli, L., Hamsten, A., Maggi, F., Eriksson, P., &
687	Catapano, A. L. (2007). Post-prandial endothelial dysfunction in hypertriglyceridemic
688	subjects: molecular mechanisms and gene expression studies. Atherosclerosis, 193(2),
689	321-327. https://doi.org/10.1016/j.atherosclerosis.2006.09.015
690	PanUKBTeam. (2020). Pan-UK Biobank https://pan.ukbb.broadinstitute.org.
691	Park, B., & Lee, Y. J. (2018). Metabolic syndrome and its components as risk factors for
692	prolonged corrected QT interval in apparently healthy Korean men and women. J Clin
693	Lipidol, 12(5), 1298-1304. https://doi.org/10.1016/j.jacl.2018.07.004
694	Peshkova, T., Nakashidze, I., Petrovic, N., Beridze, S., Kedelidze, N., Artmeladze, M., &
695	Kamashidze, K. (2020). 73 Study of lipid profile and thyroid hormones in patients with
696	uterine fibroids. International Journal of Gynecologic Cancer, 30(Suppl 3), A41-A41.
697	https://doi.org/10.1136/ijgc-2020-IGCS.69
698	Phillips, A. N., & Smith, G. D. (1991). How independent are "independent" effects? Relative risk
699	estimation when correlated exposures are measured imprecisely. J Clin Epidemiol,
700	44(11), 1223-1231. https://doi.org/10.1016/0895-4356(91)90155-3
701	Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J.,
702	Sklar, P., de Bakker, P. I. W., Daly, M. J., & Sham, P. C. (2007). PLINK: a tool set for
703	whole-genome association and population-based linkage analyses. American journal of
704	human genetics, 81(3), 559-575. https://doi.org/10.1086/519795

- 705 Qin, Z., Zhao, J., Geng, J., Chang, K., Liao, R., & Su, B. (2021). Higher Triglyceride–Glucose
- 706 Index Is Associated With Increased Likelihood of Kidney Stones [Original Research].
- 707 Frontiers in Endocrinology, 12. https://doi.org/10.3389/fendo.2021.774567
- 708 R Core Team. (2021). R: A language and environment for statistical computing. In R Foundation
- for Statistical Computing. <u>https://www.R-project.org/</u>
- 710 Richardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith,
- 711 G., & Holmes, M. V. (2020). Evaluating the relationship between circulating lipoprotein
- 712 lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian
- randomisation analysis. *PLOS Medicine*, *17*(3), e1003062-e1003062.
- 714 <u>https://doi.org/10.1371/journal.pmed.1003062</u>
- 715 Rosenson, R. S., & Goonewardena, S. N. (2021). The Residual Risk Odyssey: From LDL to

716 Lp(a)\*. Journal of the American College of Cardiology, 78(5), 434-436.

717 <u>https://doi.org/https://doi.org/10.1016/j.jacc.2021.04.103</u>

- 718 Rosenson, R. S., Shaik, A., & Song, W. (2021). New Therapies for Lowering Triglyceride-Rich
- 719 Lipoproteins: JACC Focus Seminar 3/4. *Journal of the American College of Cardiology*,

720 78(18), 1817-1830. <u>https://doi.org/https://doi.org/10.1016/j.jacc.2021.08.051</u>

- 721 Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M.,
- Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., Bonny, A., Brauer, M.,
- 723 Brodmann, M., Cahill, T. J., Carapetis, J., Catapano, A. L., Chugh, S. S., Cooper, L. T.,
- 724 Coresh, J., . . . Fuster, V. (2020). Global Burden of Cardiovascular Diseases and Risk
- Factors, 1990–2019: Update From the GBD 2019 Study. Journal of the American
- 726 *College of Cardiology*, *76*(25), 2982-3021.
- 727 <u>https://doi.org/https://doi.org/10.1016/j.jacc.2020.11.010</u>

- 728 Sanderson, E. (2021). Multivariable Mendelian Randomization and Mediation. *Cold Spring*
- 729 *Harbor Perspectives in Medicine*, 11(2), a038984.
- 730 <u>https://doi.org/10.1101/cshperspect.a038984</u>
- 731 Shaik, A., & Rosenson, R. S. (2021). Genetics of Triglyceride-Rich Lipoproteins Guide
- 732 Identification of Pharmacotherapy for Cardiovascular Risk Reduction. *Cardiovascular*

733 Drugs and Therapy, 35(3), 677-690. <u>https://doi.org/10.1007/s10557-021-07168-0</u>

- 734 Shih, C. W., Chen, Y. H., & Chen, W. L. (2022). Percentage of body fat is associated with
- increased risk of diverticulosis: A cross sectional study. *PLOS ONE*, *17*(3), e0264746.
- 736 <u>https://doi.org/10.1371/journal.pone.0264746</u>
- 737 Skrivankova, V. W., Richmond, R. C., Woolf, B. A. R., Yarmolinsky, J., Davies, N. M.,
- 738 Swanson, S. A., VanderWeele, T. J., Higgins, J. P. T., Timpson, N. J., Dimou, N.,
- 739 Langenberg, C., Golub, R. M., Loder, E. W., Gallo, V., Tybjaerg-Hansen, A., Davey
- 740 Smith, G., Egger, M., & Richards, J. B. (2021). Strengthening the Reporting of
- 741 Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-
- 742 MR Statement. JAMA, 326(16), 1614-1621. <u>https://doi.org/10.1001/jama.2021.18236</u>
- 743 Smith, J. G., Luk, K., Schulz, C.-A., Engert, J. C., Do, R., Hindy, G., Rukh, G., Dufresne, L.,
- Almgren, P., Owens, D. S., Harris, T. B., Peloso, G. M., Kerr, K. F., Wong, Q., Smith, A.
- 745 V., Budoff, M. J., Rotter, J. I., Cupples, L. A., Rich, S., . . . Aging Research in Genetic
- 746 Epidemiology Extracoronary Calcium Working, G. (2014). Association of Low-Density
- 747 Lipoprotein Cholesterol–Related Genetic Variants With Aortic Valve Calcium and
- 748 Incident Aortic Stenosis. *JAMA*, *312*(17), 1764-1771.
- 749 <u>https://doi.org/10.1001/jama.2014.13959</u>

750	Sofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T.,
751	Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., Wareham, N., Khaw, K. T., Kumari,
752	M., Kivimaki, M., Marmot, M., Asselbergs, F. W., van der Harst, P., Dullaart, R. P.,
753	Navis, G., Casas, J. P. (2010). Separating the mechanism-based and off-target actions
754	of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
755	Circulation, 121(1), 52-62. https://doi.org/10.1161/circulationaha.109.865444
756	Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P.,
757	Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A.,
758	Sprosen, T., Peakman, T., & Collins, R. (2015). UK Biobank: An Open Access Resource
759	for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age.
760	PLOS Medicine, 12(3), e1001779. https://doi.org/10.1371/journal.pmed.1001779
761	Tonoyan, N. M., Chagovets, V. V., Starodubtseva, N. L., Tokareva, A. O., Chingin, K.,
762	Kozachenko, I. F., Adamyan, L. V., & Frankevich, V. E. (2021). Alterations in lipid
763	profile upon uterine fibroids and its recurrence. Scientific Reports, 11(1), 11447.
764	https://doi.org/10.1038/s41598-021-89859-0
765	Triglyceride Coronary Disease Genetics, C., Emerging Risk Factors, C., Sarwar, N., Sandhu, M.
766	S., Ricketts, S. L., Butterworth, A. S., Di Angelantonio, E., Boekholdt, S. M., Ouwehand,
767	W., Watkins, H., Samani, N. J., Saleheen, D., Lawlor, D., Reilly, M. P., Hingorani, A. D.,
768	Talmud, P. J., & Danesh, J. (2010). Triglyceride-mediated pathways and coronary
769	disease: collaborative analysis of 101 studies. Lancet (London, England), 375(9726),
770	1634-1639. https://doi.org/10.1016/S0140-6736(10)60545-4
771	Uimari, O., Auvinen, J., Jokelainen, J., Puukka, K., Ruokonen, A., Järvelin, MR., Piltonen, T.,
772	Keinänen-Kiukaanniemi, S., Zondervan, K., Järvelä, I., Ryynänen, M., & Martikainen, H.

- 773 (2016). Uterine fibroids and cardiovascular risk. *Human Reproduction*, 31(12), 2689-
- 774 2703. <u>https://doi.org/10.1093/humrep/dew249</u>
- 775 Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., &
- 776 Nordestgaard, B. G. (2013). Remnant cholesterol as a causal risk factor for ischemic
- 777 heart disease. *J Am Coll Cardiol*, *61*(4), 427-436.
- 778 <u>https://doi.org/10.1016/j.jacc.2012.08.1026</u>
- 779 Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018). Detection of widespread horizontal
- 780 pleiotropy in causal relationships inferred from Mendelian randomization between
- 781 complex traits and diseases. *Nature Genetics*, *50*(5), 693-698.
- 782 <u>https://doi.org/10.1038/s41588-018-0099-7</u>
- 783 White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W.,
- 784 Sattar, N., Humphries, S. E., Hingorani, A. D., & Holmes, M. V. (2016). Association of
- 785 Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA cardiology,

786 *1*(6), 692-699. <u>https://doi.org/10.1001/jamacardio.2016.1884</u>

- 787 Willer, C. J., Schmidt, E. M., Sengupta, S., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A.,
- 788 Chen, J., Buchkovich, M. L., Mora, S., Beckmann, J. S., Bragg-Gresham, J. L., Chang, H.
- 789 Y., Demirkan, A., Den Hertog, H. M., Do, R., Donnelly, L. A., Ehret, G. B., Esko, T., ...
- Abecasis, G. R. (2013). Discovery and refinement of loci associated with lipid levels. *Nat*
- 791 *Genet*, 45(11), 1274-1283. <u>https://doi.org/10.1038/ng.2797</u>
- Yu, X., Wang, T., Huang, S., & Zeng, P. (2021). Evaluation of the causal effects of blood lipid
- 793 levels on gout with summary level GWAS data: two-sample Mendelian randomization
- and mediation analysis. *Journal of Human Genetics*, 66(5), 465-473.
- 795 <u>https://doi.org/10.1038/s10038-020-00863-0</u>

- 796 Zewinger, S., Reiser, J., Jankowski, V., Alansary, D., Hahm, E., Triem, S., Klug, M., Schunk, S.
- J., Schmit, D., Kramann, R., Körbel, C., Ampofo, E., Laschke, M. W., Selejan, S.-R.,
- 798 Paschen, A., Herter, T., Schuster, S., Silbernagel, G., Sester, M., ... Speer, T. (2020).
- Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome
- 800 activation. *Nature Immunology*, 21(1), 30-41. <u>https://doi.org/10.1038/s41590-019-0548-1</u>

## 802 Supplementary files

# 803 S1 Table. Causal estimates of plasma TG levels on 2,600 traits in UKB using multiple MR 804 methods.

- 805 Shown are the estimates, standard deviations, and *p*-values of MR results using IVW, MR-Egger,
- and Weighted Median methods. 141 SNPs were used as instrumental variables to proxy plasma
- 807 TG levels. A Bonferroni threshold for statistical significance was set to  $p < 0.05 / 2600 = 1.92 \times$
- $10^{-5}$  for this discovery analysis.
- 809

```
810 S2 Table. Causal estimates of plasma TG levels on 221 traits in FinnGen using multiple
```

- 811 MR methods.
- 812 Shown are the estimates, standard deviations, and *p*-values of MR results using IVW, MR-Egger,
- 813 and Weighted Median methods. 1,248 SNPs were used as instrumental variables to proxy plasma
- TG levels. A Bonferroni threshold for statistical significance was set to  $p < 0.05 / 221 = 2.26 \times$
- $10^{-4}$  for this replication analysis.

816

# 817 S3 Table. IVW-MR estimates of significant and replicated associations (Tier 1-3) after MR818 PRESSO outlier tests using UKB data.

819 Shown are the estimates, standard deviations, and *p*-values of IVW-MR results in the discovery

820 analysis, before and after outlier IV removal, for significant and replicated traits (tier 1-3) that

- had significant MR-PRESSO global test results (p < 0.05) in the primary IVW analysis of the
- 822 discovery UKB cohort.

### 824 S4 Table. Multivariable IVW-MR estimates of plasma TG levels on significant and

#### 825 replicated associations (Tier 1-3) using UKB data.

- 826 Shown are the estimates, standard deviations, and *p*-values of multivariable IVW-MR results
- 827 controlling for HDL-C, LDL-C, or both, in the discovery stage. Only tier 1-3 results significant
- 828 and replicated as predefined in the methods were examined in this analysis.